HRMY Q2 2022 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$107M+45.0% YoY

Gross Profit

$88M82.3% margin

Operating Income

$33M30.9% margin

Net Income

$24M22.0% margin

EPS (Diluted)

$0.39

QoQ Revenue Growth

+25.5%

Cash Flow

Operating Cash Flow

$34M

Free Cash Flow

$34M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$505M

Total Liabilities

$259M

Stockholders' Equity

$247M

Cash & Equivalents

$237M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$107M	$74M	+45.0%
Gross Profit	$88M	$61M	+44.1%
Operating Income	$33M	$23M	+42.1%
Net Income	$24M	$14M	+66.7%

Geographic Segments

United States

$500M100%